FINWIRES · TerminalLIVE
FINWIRES

傑富瑞表示,中東衝突擾亂了奧克蘭國際機場的客運量復甦步伐。

-- 傑富瑞(Jefferies)週四發布的一份報告指出,由於中東衝突持續,航空公司面臨燃油成本上漲的困境,奧克蘭國際機場(ASX:AIA,NZE:AIA)的客運量預期復甦速度受到衝擊。 這家股票研究公司表示,由於燃油成本高企,多家航空公司已削減運力,奧克蘭機場第四季的國際航班座位運力也因此下降,座位成長率從2月的8.5%放緩至1%。 傑富瑞表示:「鑑於中東衝突仍在持續,我們認為目前國際運力成長計畫(2027年上半年)存在下行風險,預計成長率將為4.2%。」報告也指出,面對燃油價格上漲帶來的現金流和資產負債表壓力,航空公司可能會採取運力控制和定價策略來保護利潤率。 傑富瑞將奧克蘭國際機場2026財年的客運量預測下修0.5%,2027財年調降2.5%,2028財年調降3%。 傑富瑞將奧克蘭國際機場的目標股價從8.64紐西蘭元下調至8.49紐西蘭元,但維持「持有」評級。傑富瑞表示,自2月下旬以來,該公司股價表現遜於產業和市場整體水平,這種表現已經過頭。

Related Articles

Asia

National Australia Bank Shares Down After Resolution of Union Court Proceedings

National Australia Bank (ASX:NAB) shares were down about 1% in recent Monday trade following a Friday settlement with the Finance Sector Union of Australia to resolve court proceedings related to excessive additional working hours for employees.The settlement, reached on a without-admissions basis through mediation, includes the establishment of a health, safety, and well-being framework to mitigate the risks linked to working additional hours, and calls for greater oversight of such risks.The union and the bank said in a joint statement that they are "committed to continuing to work together to ensure fair and sustainable outcomes for all [National Australia Bank] employees."

$ASX:NAB
Asia

Clinuvel Pharmaceuticals Says FDA Removes Post-Authorization Requirement for Implant

Clinuvel Pharmaceuticals (ASX:CUV) said the US Food and Drug Administration (FDA) removed a requirement for a post-authorization phase one study on cardiac repolarization in relation to its Scenesse implant upon reviewing its long-term safety profile, according to a Monday filing with the Australian bourse.Scenesse is used to treat patients with erythropoietic protoporphyria, a disease that causes intolerance to light.The FDA concluded that the study was no longer needed since it would not yield valuable safety information, the filing said.

$ASX:CUV
Asia

XRF Scientific Completes Acquisition of Combustion Gas Analysis Business

XRF Scientific (ASX:XRF) has completed the acquisition of the combustion gas analysis business from Bruker AXS, according to a Monday Australian bourse filing.The company entered a binding agreement to acquire the combustion gas analysis business for $4 million upfront plus a potential $1 million earnout based on 7% of net revenue over three years, an earlier filing showed.

$ASX:XRF